99 related articles for article (PubMed ID: 8363604)
1. Three-dimensional recognition requirements for angiotensin agonists: a novel solution for an old problem.
Nikiforovich GV; Marshall GR
Biochem Biophys Res Commun; 1993 Aug; 195(1):222-8. PubMed ID: 8363604
[TBL] [Abstract][Full Text] [Related]
2. Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications.
Zhang WJ; Nikiforovich GV; Pérodin J; Richard DE; Escher E; Marshall GR
J Med Chem; 1996 Jul; 39(14):2738-44. PubMed ID: 8709104
[TBL] [Abstract][Full Text] [Related]
3. Conformational analysis of two cyclic analogs of angiotensin: implications for the biologically active conformation.
Nikiforovich GV; Kao JL; Plucinska K; Zhang WJ; Marshall GR
Biochemistry; 1994 Mar; 33(12):3591-8. PubMed ID: 8142357
[TBL] [Abstract][Full Text] [Related]
4. Structural features of angiotensin II which are important for biologic activity.
Peach MJ
Kidney Int Suppl; 1979 Mar; (9):S3-6. PubMed ID: 289861
[TBL] [Abstract][Full Text] [Related]
5. On the molecular basis of the recognition of angiotensin II (AII). NMR structure of AII in solution compared with the X-ray structure of AII bound to the mAb Fab131.
Tzakos AG; Bonvin AM; Troganis A; Cordopatis P; Amzel ML; Gerothanassis IP; van Nuland NA
Eur J Biochem; 2003 Mar; 270(5):849-60. PubMed ID: 12603318
[TBL] [Abstract][Full Text] [Related]
6. Conformation-function relationships in LHRH analogs. II. Conformations of LHRH peptide agonists and antagonists.
Nikiforovich GV; Marshall GR
Int J Pept Protein Res; 1993 Aug; 42(2):181-93. PubMed ID: 8407112
[TBL] [Abstract][Full Text] [Related]
7. Proposals for the angiotensin II receptor-bound conformation by comparative computer modeling of AII and cyclic analogs.
Joseph MP; Maigret B; Scheraga HA
Int J Pept Protein Res; 1995 Dec; 46(6):514-26. PubMed ID: 8748712
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and AT2 receptor-binding properties of angiotensin II analogues.
Rosenström U; Sköld C; Lindeberg G; Botros M; Nyberg F; Hallberg A; Karlén A
J Pept Res; 2004 Nov; 64(5):194-201. PubMed ID: 15485557
[TBL] [Abstract][Full Text] [Related]
9. [Structure-activity organization of angiotensin II molecules. I. The structural problem].
Gogitidze TV; Popov EM
Bioorg Khim; 1993 May; 19(5):517-35. PubMed ID: 8318022
[TBL] [Abstract][Full Text] [Related]
10. On the structural basis of the hypertensive properties of angiotensin II: a solved mystery or a controversial issue?
Tzakos AG; Gerothanassis IP; Troganis AN
Curr Top Med Chem; 2004; 4(4):431-44. PubMed ID: 14965310
[TBL] [Abstract][Full Text] [Related]
11. Models for the A- and B-receptor-bound conformations of CCK-8.
Nikiforovich GV; Hruby VJ
Biochem Biophys Res Commun; 1993 Jul; 194(1):9-16. PubMed ID: 8333874
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of various proposed models of the receptor-bound conformation of H-Tyr-Tic-Phe-OH related delta-opioid antagonists.
Wilkes BC; Schiller PW
Biopolymers; 1995; 37(6):391-400. PubMed ID: 8589244
[TBL] [Abstract][Full Text] [Related]
13. The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II.
Matsoukas JM; Polevaya L; Ancans J; Mavromoustakos T; Kolocouris A; Roumelioti P; Vlahakos DV; Yamdagni R; Wu Q; Moore GJ
Bioorg Med Chem; 2000 Jan; 8(1):1-10. PubMed ID: 10968258
[TBL] [Abstract][Full Text] [Related]
14. An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations.
Mavromoustakos T; Kolocouris A; Zervou M; Roumelioti P; Matsoukas J; Weisemann R
J Med Chem; 1999 May; 42(10):1714-22. PubMed ID: 10346924
[TBL] [Abstract][Full Text] [Related]
15. Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping.
Mottola DM; Laiter S; Watts VJ; Tropsha A; Wyrick SD; Nichols DE; Mailman RB
J Med Chem; 1996 Jan; 39(1):285-96. PubMed ID: 8568818
[TBL] [Abstract][Full Text] [Related]
16. Structure and dynamics of micelle-bound neuropeptide Y: comparison with unligated NPY and implications for receptor selection.
Bader R; Bettio A; Beck-Sickinger AG; Zerbe O
J Mol Biol; 2001 Jan; 305(2):307-29. PubMed ID: 11124908
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional molecular models of the hMC1R melanocortin receptor: complexes with melanotropin peptide agonists.
Haskell-Luevano C; Sawyer TK; Trumpp-Kallmeyer S; Bikker JA; Humblet C; Gantz I; Hruby VJ
Drug Des Discov; 1996 Dec; 14(3):197-211. PubMed ID: 9017363
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the active conformation of angiotensin II: a comparison of AII and non-peptide AII antagonists.
Pierson ME; Freer RJ
Pept Res; 1992; 5(2):102-5. PubMed ID: 1581636
[TBL] [Abstract][Full Text] [Related]
19. Structural similarities of micelle-bound peptide YY (PYY) and neuropeptide Y (NPY) are related to their affinity profiles at the Y receptors.
Lerch M; Mayrhofer M; Zerbe O
J Mol Biol; 2004 Jun; 339(5):1153-68. PubMed ID: 15178255
[TBL] [Abstract][Full Text] [Related]
20. [A turning point in the knowledge of the structure-function-activity relations of elastin].
Alix AJ
J Soc Biol; 2001; 195(2):181-93. PubMed ID: 11727705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
